WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Thursday said it approved one-third more generic drugs last fiscal year and said it planned to speed review of these cheaper versions of brand-name drugs.Officials said the push includes an expedited review process using an updated electronic format and team reviews of multiple applications for the same product.
